| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 6541.2 | 7074.5 | 6729.7 |
| Other income | 148.2 | 206.3 | 289.5 |
| Total income | 6689.4 | 7280.8 | 7019.1 |
| Profit before exceptional items & tax | 707.1 | 1169.0 | 1504.3 |
| Exceptional items | 0.0 | -275.9 | 0.0 |
| Profit before tax | 707.1 | 893.1 | 1504.3 |
| Net profit | 542.5 | 674.2 | 1214.1 |
| Operating margin | 10.6% | 12.3% | 21.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -55.30% |
|---|---|
| Net profit, quarter on quarter | -19.50% |
| Revenue, year on year | -2.80% |
BSE results filing, NSE: CIPLA. Figures extracted from the filing.
Cipla Ltd: key numbers
- Share price
- ₹1,399.70
- Market cap
- ₹1,13,076 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 33.5×Sector 50.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Earnings Call Transcript: Key Takeaways
Cipla delivered record Q1 FY27 revenue of INR 7,119 Cr with 2% reported growth (4% adjusted). Strategy focuses on U.S. respiratory launches and 'One India' chronic therapies.
Cipla Investor Presentation: Key Takeaways
Cipla delivered record Q1 revenue of INR 7,119 Cr, driven by strong growth in India and the US. EBITDA margins stood at 16.7% with PAT at INR 789 Cr.